Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Aytu Biopharma

27/09/2021 22:01

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss of 75 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 49 cents per share.
* Revenue rose 58% to $23.48 million from a year ago;  analysts
expected $20.90 million. 
* Aytu Biopharma Inc's reported EPS for the quarter was a loss
of 81 cents​.
* The mean earnings estimate of analysts had fallen by
about 58.1% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Aytu Biopharma Inc shares had fallen by 40.7% this quarter and
lost 50.3% so far this year.
* The company reported a quarterly loss of $19 million.
* Wall Street's median 12-month price target for Aytu Biopharma
Inc is $17.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated September 27 at 09:01 p.m.
 ​All figures in US dollars unless otherwise stated